Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Mirum Pharmaceuticals, Inc. - common stock
(NQ:
MIRM
)
105.10
+2.27 (+2.21%)
Streaming Delayed Price
Updated: 4:00 PM EST, Feb 18, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Mirum Pharmaceuticals, Inc. - common stock
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
Why This Private Equity-Style Fund Just Bet $17 Million on Lumen Technologies Stock
↗
November 27, 2025
One small-cap specialist just made a surprisingly large bet on one of telecom’s most complicated turnarounds.
Via
The Motley Fool
Penn Capital Unwinds $17.1 Million BGC Stake as Broker Posts 31% Revenue Surge
↗
November 27, 2025
This private-equity-style shop trimmed its position in a financial technology firm that's posting record numbers despite a steep stock decline.
Via
The Motley Fool
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
November 25, 2025
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Earnings Scheduled For November 4, 2025
↗
November 04, 2025
Via
Benzinga
Earnings Scheduled For August 6, 2025
↗
August 06, 2025
Via
Benzinga
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 10, 2025
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals Showcases Leadership in Liver Disease Innovation With Data From LIVMARLI® and Volixibat Clinical Programs at AASLD’s The Liver Meeting®
November 07, 2025
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
What Analysts Are Saying About Mirum Pharmaceuticals Stock
↗
November 05, 2025
Via
Benzinga
Mirum Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update
November 04, 2025
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
November 03, 2025
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals to Announce Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025
October 28, 2025
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals Inc (NASDAQ:MIRM) Presents a Compelling Growth Momentum and Technical Setup
↗
October 18, 2025
Mirum Pharmaceuticals (MIRM) shows strong revenue growth and a positive technical setup, presenting a compelling case for momentum investors seeking breakout opportunities.
Via
Chartmill
8 Analysts Assess Mirum Pharmaceuticals: What You Need To Know
↗
October 16, 2025
Via
Benzinga
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
October 10, 2025
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals Inc (NASDAQ:MIRM) Combines Strong Growth Momentum with Bullish Technical Setup
↗
September 27, 2025
Mirum Pharmaceuticals (MIRM) shows strong growth momentum with accelerating revenue and earnings, combined with a top-rated technical setup suggesting a potential breakout.
Via
Chartmill
This Riot Platforms Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
↗
September 24, 2025
Via
Benzinga
Demystifying Mirum Pharmaceuticals: Insights From 6 Analyst Reviews
↗
September 12, 2025
Via
Benzinga
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 10, 2025
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals Announces Enrollment Completion in the Phase 2b VISTAS Study
September 08, 2025
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
MIRUM PHARMACEUTICALS INC (NASDAQ:MIRM) Shows High Growth Momentum and Technical Breakout Potential
↗
September 05, 2025
Mirum Pharmaceuticals (MIRM) shows strong growth momentum with 62% revenue growth and a bullish technical breakout pattern, making it a top biotech stock to watch.
Via
Chartmill
MIRUM PHARMACEUTICALS INC (NASDAQ:MIRM) Screens as a High-Growth Momentum Stock Using Minervini Trend Template
↗
August 30, 2025
MIRUM Pharmaceuticals (MIRM) is a high-growth stock exhibiting a strong technical uptrend and robust revenue growth, making it a standout candidate for momentum investors.
Via
Chartmill
Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
August 27, 2025
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Deep Dive Into Mirum Pharmaceuticals Stock: Analyst Perspectives (6 Ratings)
↗
August 08, 2025
Via
Benzinga
Mirum Pharmaceuticals Inc (NASDAQ:MIRM) Surpasses Q2 2025 Estimates with Strong Revenue Growth and Raised Guidance
↗
August 06, 2025
Mirum Pharmaceuticals beats Q2 2025 estimates with $127.8M revenue, narrows losses, and raises full-year guidance. Stock surges 8.6% post-earnings.
Via
Chartmill
12 Health Care Stocks Moving In Wednesday's After-Market Session
↗
August 06, 2025
Via
Benzinga
Mirum Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update
August 06, 2025
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals Inc (NASDAQ:MIRM) Fits Minervini’s Trend Template with Strong Growth Momentum
↗
August 06, 2025
Mirum Pharmaceuticals (MIRM) fits Mark Minervini's trend-following strategy with strong technicals, revenue growth, and breakout potential. A high-growth momentum stock worth watching.
Via
Chartmill
Mirum Pharmaceuticals to Announce Second Quarter 2025 Financial Results and Host Conference Call on August 6, 2025
July 30, 2025
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 10, 2025
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
June 10, 2025
From
Mirum Pharmaceuticals, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
11
12
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
